Cap: $184.2M
Runway: Late 2027
Structural Inventory: Zentalis Pharmaceuticals
ZN-C3
Azenosertib
WEE1 Inhibitor
Clinical Pipeline (Compendium View)
| Asset | Indication | Stage | Next Catalyst |
|---|---|---|---|
| Azenosertib (ZN-c3) | Cyclin E1+ Ovarian Cancer (PROC) | Phase 2 (DENALI) | Topline Data: Q4 2026 |
| Azenosertib (ZN-c3) | Platinum-Resistant Ovarian Cancer | Phase 3 (ASPENOVA) | Trial Initiation: 1H 2026 |
| Azenosertib + Bevacizumab | Ovarian Cancer (Maintenance) | Phase 2 (MUIR) | Dose Confirmation: 1H 2026 |
Latest SEC Filings
Active Clinical Trials
Operational Overview
Operational Overview
Zentalis has pivoted from a broad-platform “discovery” engine to a lean, single-asset execution machine. After the January 2025 restructuring, the company is now fully centered on validating Azenosertib as the first-in-class WEE1 inhibitor for genomic-unstable tumors.
The “Negative EV” Thesis
As of the March 2026 10-K filing, Zentalis holds $245.9M in cash against a market cap of $184M.
- The Market Signal: Investors are currently assigning a negative value to the clinical pipeline, likely due to historical safety concerns surrounding the WEE1 class and general small-cap apathy.
- The Opportunity: If the DENALI Part 2 data in Q4 2026 confirms the ~35% ORR seen in earlier cohorts with a manageable safety profile, the re-rating potential is multi-bagger in nature.
Key Risks
- WEE1 Class Toxicity: Neutropenia and thrombocytopenia remain the primary hurdles for chronic dosing. The “5:2” intermittent dosing schedule is the company’s strategic fix; 1H 2026 dose confirmation data will be the first test of this strategy.
- Financing: While runway extends into 2027, the company will likely need to raise capital on the DENALI data release to fund the full Phase 3 ASPENOVA program.